Opinion|Videos|September 4, 2024
Managed Care Strategies for Ensuring Patient Access to PDTs
Author(s)Arwen Podesta, MD
A medical expert discussses examples of successful prescription digital therapeutic (PDT) implementations and their impact on patient care, managed care coverage challenges related to PDTs, strategies to improve patient access, and methods for evaluating patient outcomes and satisfaction with PDTs.
Advertisement
Episodes in this series
- Please discuss examples of successful prescription digital therapeutic implementation and the impact on patient care.
- Have you encountered managed care coverage challenges related to prescription digital therapeutics (PDTs)?
- How can managed care help ensure that appropriate patients have access to PDTs?
- With PDTs, how are patient outcomes and patient satisfaction evaluated?
Advertisement
Related to this article
Sova, a clinical advisor for Employers Health, expects more employers to exclude GLP-1s for obesity but urges a look at coverage for specific cardiometabolic conditions.
Employers Health’s Alexis Sova says employers excluding GLP-1s now lean on weight management programs and direct-to-employer deals, not a hard cutoff.
Approximately two-thirds of Employers Health clients now exclude GLP-1s for obesity, up from a roughly even split at launch as cost drives coverage decisions.
Chad Hatfield, Pharm.D., MHA, BCPS, of UC Davis Health, discusses the system's pharmacy shared service center, embedded pharmacists and 340B rebate readiness.
Blood tests reveal early, widespread inflammation in hidradenitis suppurativa, linking biomarkers to disease severity, quality of life, smoking, and potential cardiovascular risk.
UCLA research suggests that GLP-1 therapies may protect bone health in Type 2 diabetes patients.
A study with three years of follow-up shows that the drug stays effective and safe for most, although 16% stopped getting treated with Dupixent, mainly because it was ineffective or caused side effects.
Heart disease became the leading cause of death among Hispanic adults in the U.S. in 2022, and a new American Heart Association statement says risk varies by heritage, with gaps in coverage, language and food access adding to the burden.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Dupixent shows staying power in adolescents and children with atopic dermatitis
2
Large study finds GLP-1 drugs may lower fracture risk in Type 2 diabetes
3
Systemic inflammation present even in mild hidradenitis suppurativa
4
National Alliance names interim head after arrest of its president
5